Enlivex Therapeutics
ENLV
ENLV
25 hedge funds and large institutions have $4.75M invested in Enlivex Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1% more ownership
Funds ownership: 3.62% → 4.62% (+1%)
82% less call options, than puts
Call options by funds: $56K | Put options by funds: $311K
Holders
25
Holding in Top 10
–
Calls
$56K
Puts
$311K
Top Buyers
| 1 | +$475K | |
| 2 | +$142K | |
| 3 | +$139K | |
| 4 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
+$126K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$126K |
Top Sellers
| 1 | -$125K | |
| 2 | -$63K | |
| 3 | -$39K | |
| 4 |
Renaissance Technologies
New York
|
-$22.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$22.2K |